DMAC (DiaMedica Therapeutics) Current Accrued Expense: $1.60 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $6.94
! 1 Warning Sign
View Full Analysis

What is DiaMedica Therapeutics Current Accrued Expense?

DiaMedica Therapeutics DMAC -1.70% 31 Current Accrued Expense is $1.60 Mil as of Mar. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

DiaMedica Therapeutics's Current Accrued Expense for the quarter that ended in Mar. 2026 was $1.60 Mil.

DiaMedica Therapeutics's quarterly Current Accrued Expense declined from Sep. 2025 ($2.32 Mil) to Dec. 2025 ($2.17 Mil) and declined from Dec. 2025 ($2.17 Mil) to Mar. 2026 ($1.60 Mil).

DiaMedica Therapeutics's annual Current Accrued Expense increased from Dec. 2023 ($1.01 Mil) to Dec. 2024 ($3.29 Mil) but then declined from Dec. 2024 ($3.29 Mil) to Dec. 2025 ($2.17 Mil).

DiaMedica Therapeutics Current Accrued Expense Related Terms

DiaMedica Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Current Accrued Expense Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 0.70 1.01 3.29 2.17

DiaMedica Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.71 2.16 2.32 2.17 1.60
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.60 Mil mean?
DiaMedica Therapeutics (DMAC) has a Current Accrued Expense of $1.60 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Current Accrued Expense too high?
DiaMedica Therapeutics' current Current Accrued Expense is $1.60 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Current Accrued Expense compare to PRLD and RCKT?
DiaMedica Therapeutics' Current Accrued Expense of $1.60 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Current Accrued Expense is $1.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Current Accrued Expense of $1.60 Mil. The current Current Accrued Expense is $1.60 Mil. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Current Accrued Expense is $1.60 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.94
Price